Before & After

Before and after photos from two Phase 3 studies

Baseline: Moderate (3)
Week 12: Clear (0)
Baseline: Moderate (3)
Week 12: almost Clear (1)
Baseline: Moderate (3)
Week 12: almost Clear (1)
Baseline: Moderate (3)
Week 12: almost Clear (1)

19-year-old Male: skin type iv

14-year-old male: Skin type I

19-year-old female: Skin type II

12-year-old female: Skin type V

 
 
 
 

Estimated Fitzpatrick skin type designations were assessed based on photographs post trial by a board certified dermatologist.2 Photos have not been retouched. Individual results may vary.

Patient Population

Studied in patients from various demographic,
racial, and ethnic groups1,2

Demographic

<18 years old
<18 years old
<18 years old
female
female
female

Race & Ethnicity*

HISPANIC
HISPANIC
HISPANIC
african american
african american
african american
caucasian
caucasian
caucasian

The safety and efficacy of ARAZLO Lotion were assessed in two Phase 3 trials with 1,614 subjects.1

The average patient had approximately 42 noninflammatory lesions and 28 inflammatory lesions.2

*African American and Caucasian were the top 2 indentified races within the trials while Hispanic is a representation of ethnicity.2

Study design
close

The safety and efficacy of once-daily ARAZLO Lotion were assessed in 2 multicenter, randomized, double-blind Phase 3 clinical trials of 1,614 subjects 9 years of age and older with facial acne vulgaris. Enrolled subjects had a score of moderate (3) or severe (4) on the Evaluator’s Global Severity Score (EGSS), 20 to 50 inflammatory lesions (papules, pustules, and nodules), 25 to 100 noninflammatory lesions (open and closed comedones), and 2 or fewer facial nodules. The coprimary efficacy endpoints of success on the EGSS, absolute change in noninflammatory lesion count, and absolute change in inflammatory lesion count were assessed at Week 12.1

close
close